[T&G: an elementary integrated prognostic system for renal carcinoma N0 M0].
BACKGROUND
25-30% of patients with renal cell carcinoma (RCC) develop metastatic progression during follow up. For this reason many prognostic systems have been developed to try to predict the possibility of recurrence. Unfortunately these systems are often complex in daily use.


METHODS
1089 were selected from a total of 1985 patients undergoing surgery for renal cell cancer. We have excluded patients with a benign diagnosis, lymph node or distant metastases at diagnosis, with no radical surgery (R1) and those with follow up judged insufficient (<24 months). For each patient a score was defined after evaluating the histological examination of surgical specimens. This score was called T&G and it was equal to the sum of the T pathological (1 for T1, 2 for T2, 3 for T3a, b, c, 4 for T4) and the G according to Fuhrman (1 for G1, 2 for G2, etc.). The range is between 2 and 8. It was then evaluated the disease-free survival according to T & G score to stratify patients into risk classes.


RESULTS
During follow-up we had recurrent disease in 246 cases (22.6%; 167 metastases in a single location, 34 local recurrences, 45 metastases) after surgery at a mean distance of 35.6 months (2-205). After comparing each one of the disease free survival curves, we have identified three classes of risk: low risk (T & G 2 and 3), intermediate risk (T & G 4-5), high risk (T & G 6-7-8). We have obtained statistically significant differences between the three classes of risk. The rate of progression was 8.9% for the class of low risk to 48% of the high risk class. The average time (in months) of disease progression decrease from 47 for LR class to 37 for IR up to 29 for a HR Class.


CONCLUSIONS
The T & G score is an extremely basic prognostic system but at the same time it allows an accurate prognostic discrimination in patients with N0 M0 RCC, as demonstrated by the significant differences in the rates and time of progression and disease-free survival.
Divisione e Cattedra di Urologia, Spedali Civili di Brescia, Università degli Studi di Brescia, Brescia - Italy. legramanti.stefano@gmail.com
Stefano
S
Legramanti
Alessandro
A
Antonelli
Nicola
N
Arrighi
Serena
S
Corti
Tiziano
T
Zanotelli
Alberto
A
Cozzoli
Sergio
S
Cosciani Cunico
Claudio
C
Simeone
D002292:Carcinoma, Renal Cell / Q000601:surgery; D018572:Disease-Free Survival; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery; D009364:Neoplasm Recurrence, Local; D011379:Prognosis